ImmunityBio Investor Lawsuits Push Toward May 26 Lead-Plaintiff Deadline

Overview

• Hagens Berman, Rosen Law, Block & Leviton, Kessler Topaz, and Frank R. Cruz are recruiting investors for lead-plaintiff roles before the May 26, 2026 deadline.
• The proposed class covers people who bought ImmunityBio shares from Jan. 19 through Mar. 24, 2026.
• Complaints say Executive Chairman Patrick Soon‑Shiong overstated Anktiva’s capabilities, which left investors with an unreal picture of the company’s prospects.
• The FDA warned that a TV ad and a Jan. 19 podcast were false or misleading because they implied Anktiva can cure or prevent all cancer and left out that it is only approved with BCG for certain non‑muscle invasive bladder cancer.
• Following March 24 coverage of the FDA letter, ImmunityBio’s stock fell about 21%, cutting nearly $2 billion from its market value.